Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Novo Nordisk has claimed an edge in the increasingly ... clinical trials to be more effective than Wegovy at stimulating weight loss and, according to Lilly, is on course to be approved for ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

India's anti-obesity drug market shows significant growth. It has increased fourfold in five years. Lifestyle diseases and ...

Register for free now. Novo Nordisk A/S NVO has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons. Shares have plunged 44.14% over the past year ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular ... Both treatments, as well as the company's weekly weight loss injection Wegovy, contain the active ingredient ...